In the long human struggle against cancer, one of medicine's most ingenious tools—engineering a patient's own immune cells to seek and destroy tumors—has been undermined by a quiet act of self-defeat. Researchers at the University of Maryland have now identified the molecular mechanism behind this failure: a protein called cathepsin b that causes CAR T-cells to absorb fragments of the very cancer cells they attack, dulling their own effectiveness. By blocking this protein, scientists restored the cells' durability and fighting power in preclinical models, opening a path toward clinical trials
Newswise
· Jun 13, 2026
· health
· 2 min de leitura
High
Apuração: Verificado
Researchers Identify Protein Target to Boost CAR T-Cell Therapy Effectiveness
Relevant to blood cancer patients experiencing relapse within 5 years of CAR T-cell therapy treatment.
◉
Health & Medicine
8293 artigos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% correspondência
mRNA COVID Vaccines Show Survival Boost in Advanced Cancer Patients
Devdiscourse · 99% correspondência
BioNTech, OncoC4 Report 54% Death Risk Reduction for Lung Cancer Drug …
The Manila Times · 99% correspondência
Next-gen KRAS inhibitor elisrasib shows stronger response rates than f…
Medical Xpress · 99% correspondência
US Narrows Childhood Vaccine Schedule; Doctors Warn of Public Health R…
Times Now · 99% correspondência
Cobertura Relacionada
7NEWS · Aug 23
Model's Foot Cut Led to Heart Surgery, Baby Loss—Now Advocating for Better Diagnostics
Australian model Leah Ramsey lost her baby after a small foot cut triggered a rare heart infection that was repeatedly m…
Informanté · Aug 23 South Africa Shares FMD Vaccines as Region Strengthens Disease ControlsSouth Africa reports its largest-ever FMD outbreak is coming under control through accelerated vaccination and regional …
Al Jazeera · Aug 23 Solar telemedicine kiosks expand healthcare access across rural ChadSolar-powered telemedicine kiosks in rural Chad enable remote doctor consultations at a fraction of traditional travel c…
Inquirer.net · Aug 23 Prince Harry returns to UK amid family rifts, seeking reconciliation with monarchyPrince Harry and Meghan Markle are relocating back to Britain after six years in California, potentially signaling recon…
Viés e Enquadramento
⚖
Science press release with neutral reporting of university research findings on CAR T-cell therapy improvements; minimal bias detected in straightforward presentation of preclinical study results.
Bias Direction
center
Confidence
HIGH
Standard academic press release framing emphasizing research innovation and institutional achievement. Uses expert authority and sequential discovery narrative to build credibility.
remarkably effective
promising new way
continued innovation
Limitations or skeptical views on CAR T-cell therapy scalability
Cost and accessibility concerns for patients
Perspectives from competing research groups or alternative treatment approaches
Patient experience or clinical trial participant voices
Timeline to human trials and realistic commercialization expectations
Impacto Geopolítico
🌎
This is a medical research article about CAR T-cell cancer therapy improvements, not a geopolitical matter.
Escalation Risk
N/A
Confidence
HIGH
Lente Econômica
📈
University of Maryland researchers identified cathepsin b protein blocking as a method to enhance CAR T-cell therapy effectiveness, potentially improving cancer treatment outcomes and reducing relapse rates in blood cancer patients.
Market Signal
bullish
Confidence
MED
Biotechnology and Pharmaceuticals
Healthcare and Medical Devices
Cancer Treatment and Oncology
Immunotherapy Development
Patients with recurrent or difficult-to-treat blood cancers could benefit from improved CAR T-cell therapy effectiveness, potentially reducing relapse rates (currently ~5 years) and improving survival outcomes. This could reduce long-term healthcare costs and improve quality of life for cancer patients.
FDA may accelerate review pathways for improved CAR T-cell therapies based on these findings. Potential increased funding for immunotherapy research through NIH and cancer research grants. Possible updates to clinical trial protocols for CAR T-cell therapies. Insurance coverage discussions may expand as efficacy improves.